REG - hVIVO plc - Notice of Preliminary Results
RNS Number : 0412KhVIVO plc06 April 2018For immediate release 7.00am: 6 April 2018
HVIVO PLC
("hVIVO" or the "Company")
Notice of Preliminary Results
hVIVO plc (AIM: HVO) will announce its audited preliminary results for the year ended 31 December 2017 on Thursday, 19 April 2018.
For further information please contact:
hVIVO plc
+44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries
+1 919 710 9658
Susan Flood
Numis Securities Limited
+44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK)
+44 203 727 1000
Notes to Editors:
About hVIVO plc
hVIVO plc ("hVIVO") is developing a pioneering human-based analytical platform to accelerate drug discovery and development in airways diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.
This information is provided by RNSThe company news service from the London Stock ExchangeENDNORUGUMPCUPRPPA
Recent news on hVIVO
See all newsREG - hVIVO PLC - Annual Report & Notice of AGM
AnnouncementREG - hVIVO PLC - Final results
AnnouncementREG - hVIVO PLC - Notice of Results
AnnouncementREG - hVIVO PLC - Holding(s) in Company
AnnouncementRCS - European Green Trans - Intention to float on the AIM market
Announcement